Roche, Lilly drugs to be tested as Alzheimer's protection

Washington University School of Medicine in St. Louis will test drugs from Roche ($RHHBY) and Eli Lilly ($LLY) in a pioneering study that will put a new theory on preventing Alzheimer's to the test. The outcome could help pave the way for a megablockbuster approach to treating a disease that afflicts millions. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.